Skip to content

4556.T

KAINOS Laboratories,Inc.

スタンダード · 医薬品 · 医薬品 · JP

JPY 2,268.00
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
+2.6%
EBITDA
EBIT
+0.9%
EPS
+8.5%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+0.8%
EBITDA
EPS
+0.5%

Three-year CAGR

Revenue
+4.8%
EBITDA
+1.1%
EBIT
+3.3%
Net income
+7.8%
EPS
+6.4%
Free cash flow
+11.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026